4584
Kidswell Bio Corporation
キッズウェル・バイオ
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Notes
- Consolidation basisConsolidated / Since Mar 2025
Key metrics
Revenue(thousand JPY)
Mar 2022
1,569,232
Mar 2023
2,776,241
Mar 2024
2,431,236
Mar 2025
5,082,053
Mar 2026
6,589,923
Operating profit(thousand JPY)
Mar 2022
-919,118
Mar 2023
-550,929
Mar 2024
-1,335,597
Mar 2025
27,882
Mar 2026
-138,510
Operating profit margin(%)
Mar 2022
-58.57
Mar 2023
-19.84
Mar 2024
-54.93
Mar 2025
0.55
Mar 2026
-2.1
Profit before tax(thousand JPY)
Mar 2022
-533,759
Mar 2023
-656,224
Mar 2024
-1,420,527
Mar 2025
72,867
Mar 2026
-402,928
Profit(thousand JPY)
Mar 2022
-535,259
Mar 2023
-657,434
Mar 2024
-1,422,078
Mar 2025
-21,140
Mar 2026
-413,994
Total assets(thousand JPY)
Mar 2022
3,503,335
Mar 2023
3,894,765
Mar 2024
5,085,550
Mar 2025
7,008,496
Mar 2026
6,088,396
Cash and cash equivalents(thousand JPY)
Mar 2022
1,187,189
Mar 2023
1,067,162
Mar 2024
2,231,411
Mar 2025
2,995,435
Mar 2026
3,294,916
Cash flows from operating activities(thousand JPY)
Mar 2022
-1,169,561
Mar 2023
-1,421,259
Mar 2024
-453,634
Mar 2025
936,707
Mar 2026
-1,096,139
Cash flows from investing activities(thousand JPY)
Mar 2022
526,509
Mar 2023
-28,825
Mar 2024
-
Mar 2025
65,077
Mar 2026
-12,624
Cash flows from financing activities(thousand JPY)
Mar 2022
369,083
Mar 2023
1,356,312
Mar 2024
1,617,883
Mar 2025
-240,061
Mar 2026
1,397,941
Return on equity(-)
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Mar 2026
-
Equity ratio(%)
Mar 2022
43.8
Mar 2023
26.6
Mar 2024
13.2
Mar 2025
19.1
Mar 2026
26.4
Earnings per share(JPY per share)
Mar 2022
-17.35
Mar 2023
-20.77
Mar 2024
-40.23
Mar 2025
-0.52
Mar 2026
-8.48
Net assets per share(JPY per share)
Mar 2022
48.79
Mar 2023
32.36
Mar 2024
21.35
Mar 2025
30.5
Mar 2026
32.37
Dividend per share(-)
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Mar 2026
-
Payout ratio(-)
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Mar 2026
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.